James Rho, MD
Interventional Pain Medicine · Rancho Cucamonga, CANPI 1548323769
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.1% of the total across 1,701 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 60 manufacturers, the largest accounting for just 12.8% — the pattern of someone who eats at a lot of different presentations. Among interventional pain medicine clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,701 payments — averaging $21.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$5K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$3K
- AbbVie$3K
- Spinal Simplicity, LLC$3K
- Pfizer$2K
- Forte Bio-pharma LLC$2K
- plus $19K from 54 others
What the payments were for
- Travel & lodging$1,1843%
- Food & beverage$33,02292%
- Education$1,6575%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HA MINUTEMAN G3-R$2,451
- Proclaim Family of SCS IPGs$1,409
- Intracept$971
- SPRINT PNS System$540
- INTELLIS ADAPTIVESTIM$385
- AIMOVIG$353
- Evoke$186
- Senza$173
- Morphabond ER$151
- PROCLAIM$150
- OSTEOCOOL RF ABLATION SYSTEM$149
- INCEPTIV$141
- Nalu Neurostimulation System$139
- Evoke SCS$137
- KYPHON EXPRESS II KYPHOPAK TRAY$132
- INTELLIS$126
- VOQUEZNA$125
- UBRELVY$125
- Superion ISS$125
- NURTEC ODT$124
How this compares
$35,863 in reported general payments places this provider in the 90th percentile of 188 interventional pain medicine providers in California.
See all interventional pain medicine providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 694 | $225,380 |
| OxycontinOxycodone Hcl | 168 | $189,286 |
| Nurtec OdtRimegepant Sulfate | 155 | $169,756 |
| RelistorMethylnaltrexone Bromide | 65 | $152,770 |
| Levorphanol Tartrate | 44 | $80,681 |
| LinzessLinaclotide | 140 | $76,018 |
| QuliptaAtogepant | 59 | $63,959 |
| UbrelvyUbrogepant | 63 | $62,983 |
| Xtampza ErOxycodone Myristate | 72 | $55,218 |
| Nucynta ErTapentadol Hcl | 29 | $42,254 |
| Diclofenac Sodium | 204 | $41,646 |
| Aimovig AutoinjectorErenumab-Aooe | 47 | $33,737 |
| Fentanyl | 319 | $32,471 |
| ZtlidoLidocaine | 52 | $28,600 |
| TrintellixVortioxetine Hydrobromide | 49 | $23,312 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Qulipta, Ubrelvy | $2,575 | $202,960262 claims |
| PfizerNurtec Odt, Lyrica | $2,284 | $185,139173 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $2,861 | $152,77065 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er, Nucynta Er, Belbuca, Nucynta | $1,243 | $128,778137 claims |
| Virtus Pharmaceuticals LLCLevorphanol Tartrate | $463 | $80,68144 claims |
| Scilex Pharmaceuticals Inc.Ztlido | $649 | $28,60052 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $526 | $23,31249 claims |
| Redhill Biopharma Inc.Movantik | $157 | $20,99352 claims |
| MerckBelsomra | $191 | $20,06848 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $106 | $6,05712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 188 interventional pain medicine providers in California.
Other interventional pain medicine in Rancho Cucamonga
- Michael Verdolinla Mesa$507K
- Tim LeierRancho Mirage$449K
- Jonathan GrossmanVisalia$404K
- Kasra MaasumiRancho Santa Margarita$388K
- Andrew GermanovichRancho Mirage$333K
- David LeeYorba Linda$257K
- Standiford HelmOrange$254K
- Patrick BuchananCamarillo$219K
- Chau VuSanta Rosa$141K
- Phillip LimBuena Park$127K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.